Pfizer (PFE) Stock: RSV Safety Review Adds Volatility Ahead of Market Open
TLDRs;
- FDA review of RSV therapies introduces fresh volatility for Pfizer before Wednesday’s opening bell.
- New YaoPharma obesity-pill partnership reshapes investor sentiment after mixed Tuesday trading.
- Dividend yield above 6% cushions downside but highlights ongoing skepticism in markets.
- Traders eye pre-market momentum as obesity, RSV, and macro risks collide.
Pfizer Inc. (NYSE: PFE) enters the December 10 trading session facing a rare convergence of catalysts, with a newly announced obesity-drug licensing pact and ongoing regulatory scrutiny in the RSV space sending the stock on a volatile path.
After a turbulent Tuesday session that saw shares close lower before stabilizing slightly after hours, the company’s RSV…
